JP2022538299A5 - - Google Patents
Info
- Publication number
- JP2022538299A5 JP2022538299A5 JP2021577424A JP2021577424A JP2022538299A5 JP 2022538299 A5 JP2022538299 A5 JP 2022538299A5 JP 2021577424 A JP2021577424 A JP 2021577424A JP 2021577424 A JP2021577424 A JP 2021577424A JP 2022538299 A5 JP2022538299 A5 JP 2022538299A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025000024A JP2025060984A (ja) | 2019-06-27 | 2025-01-05 | Ｃｎｓ障害を治療するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867618P | 2019-06-27 | 2019-06-27 | |
| US62/867,618 | 2019-06-27 | ||
| PCT/US2020/040153 WO2020264509A1 (en) | 2019-06-27 | 2020-06-29 | Compositions and methods for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025000024A Division JP2025060984A (ja) | 2019-06-27 | 2025-01-05 | Ｃｎｓ障害を治療するための組成物及び方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022538299A JP2022538299A (ja) | 2022-09-01 |
| JPWO2020264509A5 JPWO2020264509A5 (https=) | 2023-07-07 |
| JP2022538299A5 true JP2022538299A5 (https=) | 2023-07-07 |
| JP7787635B2 JP7787635B2 (ja) | 2025-12-17 |
Family
ID=71728947
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577424A Active JP7787635B2 (ja) | 2019-06-27 | 2020-06-29 | Ｃｎｓ障害を治療するための組成物及び方法 |
| JP2025000024A Pending JP2025060984A (ja) | 2019-06-27 | 2025-01-05 | Ｃｎｓ障害を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025000024A Pending JP2025060984A (ja) | 2019-06-27 | 2025-01-05 | Ｃｎｓ障害を治療するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12552829B2 (https=) |
| EP (1) | EP3990469A1 (https=) |
| JP (2) | JP7787635B2 (https=) |
| KR (1) | KR20220038680A (https=) |
| CN (1) | CN114391019A (https=) |
| AR (1) | AR119305A1 (https=) |
| AU (1) | AU2020302748A1 (https=) |
| BR (1) | BR112021026462A2 (https=) |
| CA (1) | CA3143509A1 (https=) |
| IL (1) | IL289172A (https=) |
| MX (3) | MX2021015942A (https=) |
| TW (1) | TWI896547B (https=) |
| WO (1) | WO2020264509A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| JP7787635B2 (ja) * | 2019-06-27 | 2025-12-17 | セージ セラピューティクス， エルエルシー | Ｃｎｓ障害を治療するための組成物及び方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2969M (fr) | 1963-05-22 | 1964-11-30 | Roussel Uclaf | Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale. |
| ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4060295A (en) | 1976-03-15 | 1977-11-29 | Molex Incorporated | Zero insertion force printed circuit board edge connector assembly |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| FI972202L (fi) | 1994-11-23 | 1997-07-17 | Cocensys Inc | Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| WO2005105822A2 (en) * | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| HRP20201126T1 (hr) | 2014-05-29 | 2020-12-11 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, njihovi pripravci i uporabe |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| WO2017049044A1 (en) | 2015-09-16 | 2017-03-23 | Bartolucci Giampiero | Ursodeoxycholic acid and brain disorders |
| HK1258616A1 (zh) | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| US20190233465A1 (en) * | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP3641779B1 (en) * | 2017-06-23 | 2024-02-28 | The Board of Trustees of the University of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| WO2019041078A1 (en) | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CN111741965B (zh) | 2017-12-22 | 2024-06-25 | 萨奇治疗股份有限公司 | 治疗中枢神经系统疾病的组合物和方法 |
| CN114656514B (zh) | 2018-02-11 | 2024-05-14 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| IL283629B2 (en) * | 2018-12-05 | 2026-03-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| CN116589521B (zh) | 2019-01-08 | 2025-07-11 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
| WO2020210117A1 (en) | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| WO2020210116A1 (en) | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| US20230257415A1 (en) | 2019-06-27 | 2023-08-17 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| JP7787635B2 (ja) | 2019-06-27 | 2025-12-17 | セージ セラピューティクス， エルエルシー | Ｃｎｓ障害を治療するための組成物及び方法 |
| AU2020304673A1 (en) | 2019-06-27 | 2022-01-20 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| WO2022115381A1 (en) * | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Onc. | Compositions and methods for treating cns disorders cross reference to related application |
-
2020
- 2020-06-29 JP JP2021577424A patent/JP7787635B2/ja active Active
- 2020-06-29 TW TW109121938A patent/TWI896547B/zh active
- 2020-06-29 MX MX2021015942A patent/MX2021015942A/es unknown
- 2020-06-29 US US17/620,226 patent/US12552829B2/en active Active
- 2020-06-29 AR ARP200101836A patent/AR119305A1/es unknown
- 2020-06-29 AU AU2020302748A patent/AU2020302748A1/en active Pending
- 2020-06-29 CA CA3143509A patent/CA3143509A1/en active Pending
- 2020-06-29 WO PCT/US2020/040153 patent/WO2020264509A1/en not_active Ceased
- 2020-06-29 BR BR112021026462A patent/BR112021026462A2/pt unknown
- 2020-06-29 EP EP20743476.2A patent/EP3990469A1/en active Pending
- 2020-06-29 CN CN202080059463.9A patent/CN114391019A/zh active Pending
- 2020-06-29 KR KR1020227002448A patent/KR20220038680A/ko active Pending
-
2021
- 2021-12-16 MX MX2024009926A patent/MX2024009926A/es unknown
- 2021-12-16 MX MX2024009925A patent/MX2024009925A/es unknown
- 2021-12-20 IL IL289172A patent/IL289172A/en unknown
-
2025
- 2025-01-05 JP JP2025000024A patent/JP2025060984A/ja active Pending